BPMC נכסי החברה Blueprint Medicines

Blueprint Medicines (BPMC) acts as an innovator in precision therapy, utilizing a unique set of protein kinases to combat rare mutations. The operating model is based on outsourcing clinical trials and manufacturing to third-party contractors, which creates a dependency on partners. The price action of total assets, which currently stands at 1117.14, confirms financial stability supported by steady demand and high margins for the core drug.

For the long-term investor, Blueprint Medicines (BPMC) represents a defensive asset due to the autonomy of the biopharmaceutical cycle, where the company's total assets—calculated reversely via ROA as the sum of equity and liabilities—reached 1117.14, confirming a systemic accumulation of resources for innovative development and ensuring fundamental business stability regardless of macroeconomic fluctuations.